Jack Phillips Sells 26,735 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,735 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $0.78, for a total value of $20,853.30. Following the completion of the transaction, the chief executive officer now directly owns 162,919 shares of the company’s stock, valued at approximately $127,076.82. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jack Phillips also recently made the following trade(s):

• On Friday, April 12th, Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.86, for a total value of $22,828.70.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total value of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total value of $642.20.

Accelerate Diagnostics Trading Up 11.6 %

Shares of AXDX stock opened at $0.86 on Friday. The stock has a market cap of $18.61 million, a price-to-earnings ratio of -0.18 and a beta of 0.52. The stock has a 50-day moving average of $0.99 and a 200-day moving average of $3.16. Accelerate Diagnostics, Inc. has a 1-year low of $0.73 and a 1-year high of $11.90.

Institutional Investors Weigh In On Accelerate Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Griffin Asset Management Inc. increased its stake in shares of Accelerate Diagnostics by 11.0% in the first quarter. Griffin Asset Management Inc. now owns 1,354,254 shares of the medical research company’s stock valued at $1,341,000 after buying an additional 134,530 shares during the period. Tejara Capital Ltd bought a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $78,000. Sonora Investment Management Group LLC bought a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $63,000. TCI Wealth Advisors Inc. bought a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $337,000. Finally, Geode Capital Management LLC boosted its position in shares of Accelerate Diagnostics by 31.8% during the 2nd quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company’s stock valued at $531,000 after purchasing an additional 158,383 shares in the last quarter. Institutional investors and hedge funds own 17.14% of the company’s stock.

Wall Street Analysts Forecast Growth

AXDX has been the subject of a number of recent research reports. Craig Hallum lowered their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a report on Monday, April 1st. William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd. Finally, StockNews.com initiated coverage on Accelerate Diagnostics in a research note on Saturday. They issued a “hold” rating for the company.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.